<unk> , sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the production of white blood cells (neutrophils).<unk>  was developed by Amgen.<unk>  treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.<unk>  has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).<unk>  was approved for medical use in the United States in January 2002, in the European Union in August 2002, and in Australia in September 2002.
Pegfilgrastim
Lipegfilgrastim
Filgrastim
Romiplostim
Interferon beta-1a
Granulocyte colony-stimulating factor
Granulocyte-macrophage colony-stimulating factor
Interferon